Haifa, Israel

Arie L Gutman

This inventor holds 23 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Finetech Laboratories Ltd., Fine Tech Corporation, Isp Investments Inc.. Active years: 2001-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arie L Gutman. Retrieved from https://idiyas.com/inventor/arie-l-gutman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 

% Patents Active = 56.5


 

Average Co-Inventor Count = 5.4

ph-index = 6

Forward Citations = 110(Granted Patents)


Company Filing History:


Years Active: 2001-2017

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Bimatoprost
Dronedarone
Dexmethylphenidate
Prostaglandin Derivatives
Cabergoline
Threo-Methylphenidate
Thebaine
Flecainide
Donepezil
Glycosidation
Polyaldimines
Moisture-Curable
23 patents (USPTO):Explore Patents

Title: The Innovations of Arie L. Gutman

Introduction

Arie L. Gutman is a prominent inventor based in Haifa, Israel, known for his significant contributions to the field of cannabinoid research. With an impressive portfolio of 23 patents, Gutman has focused on developing methods related to tetrahydrocannabinol, which is crucial for various therapeutic applications.

Latest Patents

Among his latest innovations, Gutman has disclosed methods for producing both trans-(-)-tetrahydrocannabinol and trans-(+)-tetrahydrocannabinol. One of his notable compositions achieves a remarkable purity of at least 99% by weight of trans-(-)-tetrahydrocannabinol. This composition is vital in formulating treatments aimed at alleviating conditions such as pain. By utilizing a chiral stationary phase, the separation process optimizes the purity of these cannabinoid compounds, enhancing their efficacy for medical use.

Career Highlights

Throughout his career, Arie L. Gutman has collaborated with well-established companies, including Finetech Laboratories Ltd. and Fine Tech Corporation. His role in these organizations has significantly influenced research and development in cannabinoid applications, leading to his numerous patents and academic contributions in the field.

Collaborations

Collaboration is a key aspect of Gutman's work. He has worked alongside notable colleagues such as Gennady Nisnevich and Boris Tishin. Their combined expertise has fostered innovative approaches to cannabinoid chemistry, furthering the impact of their research in therapeutic applications.

Conclusion

Arie L. Gutman continues to be a pivotal figure in the advancement of cannabinoid research and its practical applications. With his extensive patent portfolio and collaborations in the industry, he is poised to make further significant contributions to the field, enhancing the understanding and utilization of tetrahydrocannabinol in modern medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…